Documents or data files from May 2022 often contain results from the trial, which evaluated TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism. Key findings shared around this time included:
If this file is a laboratory or reference update, it likely addresses the ongoing challenges in : 2022 05 13 PTh actualizat.rar
: The treatment was generally well-tolerated with no treatment-related serious or severe adverse events reported through the study period. Documents or data files from May 2022 often
: Significant improvements were noted in physical and cognitive symptoms as measured by the HPES (Hypoparathyroidism Patient Experience Scale) and SF-36 surveys. Interpreting PTH Updates 2022 05 13 PTh actualizat.rar